-+ 0.00%
-+ 0.00%
-+ 0.00%

Nuvation Bio to Present Updated Phase 2 Safusidenib Results in Glioma at SNO Meeting

PUBT·11/02/2026 13:05:07
Listen to the news
Nuvation Bio to Present Updated Phase 2 Safusidenib Results in Glioma at SNO Meeting
  • Nuvation Bio will present updated Phase 2 safusidenib results Nov. 13, 2026, at the Society for Neuro-Oncology annual meeting.
  • The presentation will expand on positive topline results announced in July, with additional long-term efficacy and safety data.
  • The J201 study involves patients with Grade 2 IDH1-mutant glioma who have not received chemotherapy or radiotherapy.
  • Three other posters will outline ongoing safusidenib studies, including a Phase 3 maintenance trial in IDH1-mutant astrocytoma with high-risk features.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY84966) on November 02, 2026, and is solely responsible for the information contained therein.